High-yield dividend stocks may not appeal to some investors. However, if you're among those investors looking for income, ...

If you live in the United States, you’ve likely seen drug commercials like this one: “If you’re living with moderate to severe plaque psoriasis or active psoriatic arthritis, symptoms can sometimes ...

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and ...

Eli Lilly and Company LLY announced that the FDA has granted approval to its drug, Omvoh (mirikizumab), for its second ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.

“Ulcerative colitis can severely diminish a person’s quality of life and cause long-term health-related complications if it isn’t well managed,” said Professor Charlie Lees, Consultant ...

AbbVie and Gilead are going back to their roots and leaning on their established areas of expertise to set themselves up for ...

AbbVie closed out the year on a high note as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s final monthly ranking of the biggest TV ad spenders in biopharma.

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

AbbVie's IL-23 inhibitor Skyrizi trailed some of its rivals in its first indication psoriasis, but has leapfrogged into first place in Crohn's disease after getting approval for the new indication ...

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.

Crohn's disease and ulcerative colitis are idiopathic, chronic, relapsing, inflammatory conditions that are immunologically mediated. Although their exact etiologies remain uncertain, results from ...